PCORI will soon release a new funding opportunity soliciting proposals for phased, large awards for comparative clinical effectiveness research (CER) with each award allowed up to $22 million in direct costs. The proposed projects will build on an initial feasibility phase that must demonstrate a high likelihood that awardees can successfully conduct a follow-on, full-scale trial to receive continuous funding. This Funding Announcement will open on Tuesday, May 5, 2020, with more information about the funding opportunity.

This PCORI funding announcement invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions. Proposed studies should compare interventions that already have established evidence of efficacy or are in widespread use. Clinical interventions (such as medications, diagnostic tests, or procedures) and delivery system interventions are appropriate for study.

An applicant Town Hall meeting will be held May 19 from noon - 1:30 pm (ET).

LOI Due:  June 2, 2020
Invited Applications Due:  September 1, 2020
Total Direct Costs:  Feasibility Phase (18 months) - $2 million 
Full-Scale (5 years) - $20 million
Awards Announced:  March 2021